n February, Ultragenyx announced the U.S. FDA granted Priority Review for the Biologics License Application (BLA) for DTX401, an investigational genetherapy for GSDIa, andset a decision date of August 23, 2026. Priority Review does not mean approval, and FDA will evaluate the totality of the data before making a decision.